The University of Southampton
University of Southampton Institutional Repository

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome

Gross, O., Beirowski, B., Koepke, M.L., Kuck, J., Reiner, M., Addicks, K., Smyth, N., Schulze-Lohoff, E. and Weber, M. (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome Kidney International, 63, (2), pp. 438-446. (doi:10.1046/j.1523-1755.2003.00779.x).

Record type: Article

Abstract

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
Background Alport syndrome (AS) is a common hereditary cause of end-stage renal failure in adolescence due to defects in type IV collagen genes. Molecular genetics allows early diagnosis, however, no preventive strategy can be offered. Using the COL4A3 -/- mouse, an animal model for human AS, we evaluated therapy with ramipril in mice.
Methods One hundred and twenty-two Alport-mice were treated with 10 mg/kg/day ramipril added to drinking water. Proteinuria, serum-urea and lifespan were monitored. Renal matrix was characterized by immunohistochemistry, light- and electron microscopy, and Western blot.
Results Untreated COL4A3 -/- mice died from renal failure after 71 plusminus 6 days. Early therapy starting at four weeks of age and continuing to death delayed onset and reduced the extent of proteinuria. Uremia was postponed by three weeks in treated animals. Lifespan increased by more than 100% to 150 plusminus 21 days (P < 0.01). In parallel, decreased deposition of extracellular matrix and lessened interstitial fibrosis as well as reduced amounts of renal transforming growth factor-beta1 (TGF-beta1) could be demonstrated. Late therapy starting at seven weeks decreased proteinuria, however, lifespan did not increase significantly.
Conclusions The results indicate an antiproteinuric and antifibrotic nephroprotective effect of ramipril in COL4A3 -/- mice is mediated by down-regulation of TGF-beta1. This effect in mice is enhanced by initiation of therapy during pre-symptomatic disease. The data in COL4A3 -/- mice as an animal-model for Alport syndrome suggest that ramipril might as well delay renal failure in humans with AS. Early diagnosis and preemptive treatment also may be crucial in humans.

Full text not available from this repository.

More information

Published date: 1 February 2003
Keywords: hereditary kidney disease, type IV collagen, ACE-inhibitors, extracellular matrix, treatment of renal disease, ramipril

Identifiers

Local EPrints ID: 56334
URI: http://eprints.soton.ac.uk/id/eprint/56334
ISSN: 0085-2538
PURE UUID: eeff0cc6-e982-4ca0-b38d-ce63d8bf53ec

Catalogue record

Date deposited: 08 Aug 2008
Last modified: 17 Jul 2017 14:31

Export record

Altmetrics

Contributors

Author: O. Gross
Author: B. Beirowski
Author: M.L. Koepke
Author: J. Kuck
Author: M. Reiner
Author: K. Addicks
Author: N. Smyth
Author: E. Schulze-Lohoff
Author: M. Weber

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×